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Abstract
Background: Routine thrombus aspiration during primary percutaneous coronary intervention (PCI) in ST-elevation
myocardial infarction (STEMI) did not reduce the primary composite endpoint in the “A Randomised Trial of Routine
Aspiration ThrOmbecTomy With PCI Versus PCI ALone in Patients With STEMI Undergoing Primary PCI” (TOTAL) trial.
We aimed to analyse a similar endpoint in “The Thrombus Aspiration in ST-Elevation myocardial infarction in
Scandinavia” (TASTE) trial up to 180 days.
Methods: In TASTE, 7244 patients with STEMI were randomised to thrombus aspiration followed by PCI or to PCI
alone. We analysed the quadruple composite endpoint of cardiovascular death, cardiogenic shock, rehospitalisation
for myocardial infarction, or new hospitalisation for heart failure. Furthermore, an extended net-benefit composite
endpoint including stent thrombosis, target vessel revascularization or stroke within 180 days was analysed.
Results: The primary quadruple composite endpoint occurred in 8.7 % (316 of 3621) in the thrombus aspiration
group compared to 9.3 % (338 of 3623) in the PCI alone group (hazard ratio (HR), 0.93; 95 % confidence interval
(CI); 0.80 - 1.09, P = 0.36) and the extended net-benefit composite endpoint in 12.0 % (436) vs. 13.2 % (479) (HR,
0.90; 95 % CI; 0.79 - 1.03, P = 0.12). Stroke within 30 days occurred in 0.7 % (27) vs. 0.7 % (24) (HR, 0.89; 95 % CI;
0.51–1.54, P = 0.68).
Conclusions: A large and an extended composite endpoint analysis from the TASTE trial did not demonstrate any
clinical benefit of routine thrombus aspiration during PCI in patients with STEMI. There was no evidence of an
increased risk of stroke with thrombus aspiration.
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Background
Thrombus aspiration as adjunctive therapy to primary
percutaneous coronary intervention (PCI) has been a
much debated subject with conflicting results from both
randomised clinical trials and retrospective analysis from
registry databases [1–5]. The two largest randomised
trials, “The Thrombus Aspiration in ST-Elevation
myocardial infarction in Scandinavia” (TASTE, 7244
patients) trial and the recently published “A Rando-
mised Trial of Routine Aspiration ThrOmbecTomy
With PCI Versus PCI ALone in Patients With STEMI
Undergoing Primary PCI” (TOTAL, 10 732 patients)
trial were both negative regarding their primary end-
points; death at 30 days in TASTE and the composite
endpoint of cardiovascular (CV) death, recurrent
myocardial infarction (MI), cardiogenic shock or new
or worsening New York Heart Association (NYHA)
class IV heart failure (HF) within 180 days in TOTAL
[1, 5]. Together, the TASTE and TOTAL trials dwarf
all previous randomised trials of thrombus aspiration
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in number of patients randomised, but criticism has
been raised towards the TASTE trial regarding an
underpowered study with inclusion of a low risk
population, lack of evaluation of stroke rates and oc-
currence of HF post index hospitalisation as well as
no adjudication of events [6]. However, the TASTE
trial was unique because it was a prospective simple
registry based randomised clinical trial (R-RCT) with
randomisation and events solely performed and col-
lected through national health and death registries.
We now wanted to analyse the TASTE cohort of
patients, using similar endpoints collected in the
TOTAL trial, captured up to 180 days for a compos-
ite endpoint of CV death, rehospitalisation for new
MI, cardiogenic shock and rehospitalisation for HF
and also collect data for the key safety outcome of
stroke up to 30 and 180 days which has come into
question following publication of the TOTAL trial.
Methods
Study designs
The TASTE trial, ClinicalTrials.Gov Identifier NCT01093
404, was approved for Sweden (all Swedish sites) by the
Regional Ethical Committee in Uppsala, for Denmark by
the Ethical Committee Region Midt Jylland, Århus, and
for Iceland by the ethical committee at Landspítali
University Hospital Reykavik. The study complies with
the Declaration of Helsinki. Signed informed consent
was obtained from all patients.
The design, baseline characteristics and results of the
TASTE and TOTAL trials have been published previously
[1, 5–8]. Both are multicentre, prospective, randomised
clinical open-label trials in patients with ST-elevation
myocardial infarction (STEMI) evaluating use of routine
thrombus aspiration, before PCI, as compared to PCI
alone. Patients were randomised in a 1:1 fashion. The
TASTE trial performed identification of patients, ran-
domization, collection of baseline and procedural vari-
ables and follow-up from the “Swedish Web-system for
Enhancement and Development of Evidence-based care in
Heart disease Evaluated According to Recommended
Therapies” registry (SWEDEHEART), the “Swedish angi-
ography and angioplasty registry” (SCAAR), and national
population registries [9]. The TOTAL trial is a classical
randomised clinical trial (RCT) with monitoring of pa-
tients and adjudication of events as well as independent
core lab analysis of angiographic films.
The primary composite endpoint of TOTAL encom-
passed data of new or worsening HF (NYHA class IV)
and cardiogenic shock which has not previously been
reported from the TASTE trial. The primary safety end-
point of stroke up to 30 and 180 days has also not previ-
ously been reported from the TASTE trial. Data was
therefore captured from the TASTE cohort using the
international classification of disease (ICD) code data-
base within the Swedish national database “The National
Patient Registry” (NPR) from the Swedish National Health
Board (http://www.socialstyrelsen.se/english). Data from
the NPR database was then jointly analysed with the
TASTE database in SCAAR/SWEDEHEART. The small
number of patients from Denmark and Iceland were en-
tered in separately by the investigators.
Important differences between TASTE and TOTAL
The main difference between the two trials were the pri-
mary endpoints, all-cause mortality vs. a composite end-
point. Furthermore, the TASTE trial included patients
up to 24 h after onset of symptoms as opposed to 12 h
in TOTAL. Also, patients with previous coronary artery
bypass grafting (CABG) were excluded from TOTAL.
Finally, patients were randomised after the diagnostic
coronary angiogram in TASTE whereas patients in
TOTAL were randomised before the coronary angio-
gram although patients who did not undergo PCI for the
index STEMI were not included in the TOTAL’s primary
analysis.
Endpoints, outcomes, and definitions
Clinical endpoint parameters were obtained from national
health registries as described above in Sweden, Denmark
and Iceland. A small number of Danish and Icelandic pa-
tients could not be captured for cardiogenic shock and HF
(247 Danish for cardiogenic shock and 156 Icelandic for
rehospitalisation of HF). Most importantly, no study-
specific clinical follow-up was performed. The following
endpoints were thus captured; all cause death, CV death,
cardiogenic shock, rehospitalisation for new MI, hospital-
isation for new HF, stroke, definite stent thrombosis (ST)
and target vessel revascularization (TVR) up to 30 and
180 days as well as for the maximum follow up time.
The primary endpoint for the present analysis was the
quadruple composite of CV death, cardiogenic shock,
rehospitalisation with new MI and hospitalisation for
new HF corresponding to the primary outcome of the
TOTAL trial. Secondary endpoints include the individual
components of the composite in addition to stroke, def-
inite ST, TVR and all cause death. Further evaluated
composite endpoints include the net-benefit endpoint
comprised of the primary endpoint and stroke and also
the extended net-benefit endpoint comprised of the pri-
mary endpoint in addition to stroke, definite ST and TVR.
Specifically, all cause death and CV death were cap-
tured from the national death registries and national
cause of death registries. Cardiovascular deaths were
identified inclusively as deaths with the underlying cause
ICD code I00-I99 or not recorded, hence only deaths
with a recorded non-cardiac underlying cause were ex-
cluded. Stroke was captured as ICD code I60-I64, either
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as primary diagnosis for a new hospitalisation in NPR,
or as one of the discharge diagnoses for the index
hospitalisation in SWEDEHEART, with strokes during
index hospitalisation counted as occurring on the day
of randomization.
New hospitalisations with myocardial infarction were
captured using the ICD codes I20-22. New hospitalisa-
tions for HF were captured as primary diagnosis using
ICD code I50 in NPR. Cardiogenic shock was captured for
patients with Killip class I-III HF at randomization with a
new angio/PCI with Killip class IV in SCAAR or a post-
baseline record of cardiogenic chock in SWEDEHEART,
including both index and new hospitalisations.
Target lesion revascularization was defined as a new
PCI in the same coronary segment as the index proced-
ure or CABG after the index procedure and captured
from the SWEDEHEART/SCAAR registry. Stent throm-
bosis was defined as definite ST and captured from the
SWEDEHEART/SCAAR registry.
All endpoints in Denmark and all non-SWEDEHEART
based end points in Iceland were collected by the
investigators.
Statistics
The results were analysed according to the intention-to-
treat principle, i.e. patients randomised to a given group
were followed and assessed irrespective of the treatment.
Time to the composite endpoint was presented in a
Kaplan-Meier plot. The treatment hazard ratio was cal-
culated using a Cox proportional hazard model with
treatment as the only factor, and presented with its 95 %
confidence interval from the Cox model and the 2-sided
P-value from a log-rank test. Other time-to-event out-
comes were analysed in the same way. For the primary
statistical analysis events after more than 180 days (30 days
for stroke) were considered censored. Additional analyses
were performed for 180 days stroke, and using all available
follow-up. All analyses were conducted with SAS v.9.3
(SAS Institute Inc., Cary, NC, USA). A two-tailed P-value
<0.05 was considered statistically significant.
Results
Study population
Follow up was available for all patients up to 30 and
180 days as well as at the maximum follow up time,
(median 25 months). Baseline, and procedural character-
istics for all randomised patients have previously been
published [1, 8].
Clinical outcome
All analysed endpoints are listed in Table 1. For efficacy
up to 180 days, there were no significant differences in
outcome for the individual endpoints of all cause death,
CV death, rehospitalisation with new MI, definite ST,
and TVR or in combination with cardiogenic shock or
new hospitalisation with HF. The primary endpoint con-
sisting of the quadruple composite endpoint of CV
death, cardiogenic shock, rehospitalisation with new MI,
new hospitalisation for HF up to 180 days occurred in
8.7 % (316 of 3621) in the thrombus aspiration group
compared to 9.3 % (338 of 3623) in the PCI alone group
(hazard ratio (HR), 0.93; 95 % confidence interval (CI),
0.80 - 1.09; P = 0.36) (Fig. 1a), and at maximal follow up
(25 months), in 13.3 % (483) vs. 14.4 % (521) (HR, 0.92;
95 % CI, 0.82-1.05; P = 0.21) (Fig. 1b).
Stroke within 30 days occurred in 0.7 % (24) in the
thrombus aspiration group vs. 0.7 % (27) of patients in the
PCI alone group (HR, 0.89; 95 % CI, 0.51–1.54; P = 0.68)
and within 180 days in 1.2 % (42) vs. 1.2 % (45), (HR, 0.93;
95 % CI, 0.61-1.42; P = 0.75) (Fig. 2a and b).
The net-benefit composite endpoint within 180 days,
similar to the one analysed in TOTAL, of CV death, car-
diogenic shock, rehospitalisation with new MI, new hospi-
talisation for HF or stroke occurred in 9.5 % (343) in the
PCI plus thrombus aspiration (TA) group vs. 10.2 % (371)
in the PCI alone group, (HR 0.92; 95 % CI, 0.79-1.07, P =
0.27) (Fig. 3).
The large extended net-benefit, composite endpoint of
CV death, cardiogenic shock, rehospitalisation with new
MI, new hospitalisation for HF, stroke, definite ST or
TVR up to 180 days occurred in 12.0 % (436) vs. 13.2 %
(479), (HR, 0.90; 95 % CI, 0.79 - 1.03, P = 0.12) (Fig. 4a),
and at maximal follow up (25 months) in 18.7 % (677)
vs. 20.3 % (736), (HR, 0.91; 95 % CI, 0.82-1.01, P = 0.08)
(Fig. 4b) for patients treated with thrombus aspir-
ation (TA) vs. PCI alone respectively.
Discussion
In this post hoc analysis of the TASTE study comparing
the composite endpoint of CV death, rehospitalisation
with new MI, cardiogenic shock or new hospitalisation for
HF up to 180 days between STEMI patients treated with
thrombus aspiration and PCI vs. PCI alone there was no
significant difference in outcome demonstrating a lack of
clinical effect of thrombus aspiration. There was also no
difference in stroke rates up to 30 or 180 days.
The allure of improving microvascular reperfusion in
STEMI patients through thrombus aspiration is power-
ful, especially with the frequently observed removal of
large macroscopic specimens. There are also indications
that embolization of atherothrombotic materials may
contribute to microvascular obstruction in humans [10].
Removal of thrombus would thus seem intuitive in order
to improve outcome. However a host of thrombus aspir-
ation trials have reported conflicting results and it was only
following the single centre TAPAS trial that thrombus as-
piration became widely accepted and upgraded in treat-
ment guidelines [2, 11–13].
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The TASTE trial was negative regarding the primary
endpoint of death up to 30 days as well as all second-
ary endpoints including death at one year [1, 8]. Fol-
lowing the TAPAS and TASTE trials and several meta-
analyses, there were conflicting data to support the
use of routine thrombus aspiration as adjunctive treat-
ment to PCI in STEMI patients [2, 13–15]. However,
the TASTE and the TOTAL trials, which together ran-
domised >17 000 patients, both demonstrated no clin-
ical effect of routine use of thrombus aspiration in
STEMI patients undergoing primary PCI. Both TASTE
and TOTAL were similarly negative across the board
in respect with all major secondary endpoints except
stroke up to 30 days, which in TOTAL showed a small
significantly increased risk of stroke in the thrombus
aspiration group within 30 days. However, there were
no demonstrated differences in stroke rates up to 30
or 180 days in the TASTE trial, similarly as reported
in a meta-analysis by De Luca et al. [16]. Also, the
excess of strokes in the thrombus aspiration group in
TOTAL was exceedingly small (0.7 % vs. 0.3 %) with
separating event curves after the stent procedure
which may therefore be explained by a play of chance.
With this study of the TASTE population using several
composite endpoints and an extended composite end-
point, we were still unable to demonstrate any clinical
effect of thrombus aspiration.
We can thus favourably compare the 7244 patient
TASTE trial to the 10732 patient TOTAL trial and al-
though no clinical follow up or adjudication of events
were performed in TASTE, the outcomes are very simi-
lar across all endpoints, composite endpoints and sub-
groups except stroke. However, and most importantly,
both primary endpoints conclude that there is no clinical
benefit of routine thrombus aspiration during PCI in
STEMI patients. In light of these results, the recently re-
leased AHA/ACC/SCAI focused update on primary PCI
in STEMI patients has downgraded the use of thrombus
Table 1 Outcomes for efficacy, net-benefit and safety up to 30 days, 180 days and to maximal follow-up (mean 25 months)
Outcome Thrombus aspiration
N = 3621
PCI alone
N = 3623
Hazard ratio
(95 % CI)
P-value
Efficacy up to 180 days
Cardiovascular (CV) death 125 (3.5 %) 133 (3.7 %) 0.94 (0.74-1.20) 0.62
All cause death 145 (4.0 %) 156 (4.3 %) 0.93 (0.74-1.17) 0.52
Rehospitalisation for new myocardial infarction (Rehosp-MI) 63 (1.7 %) 70 (1.9 %) 0.90 (0.64-1.26) 0.53
Definite stent thrombosis (ST) 20 (0.6 %) 26 (0.7 %) 0.77 (0.42-1.37) 0.37
Target vessel revascularization (TVR) 130 (3.6 %) 144 (4.0 %) 0.90 (0.71-1.14) 0.38
Cardiogenic chock or new hospitalisation with heart failure (HF) 176 (4.9 %) 186 (5.1 %) 0.95 (0.77-1.16) 0.59
CV death, cardiogenic shock, Rehosp-MI or new heart failure (HF)a 316 (8.7 %) 338 (9.3 %) 0.93 (0.80-1.09) 0.36
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, definite ST or TVR 409 (11.3 %) 448 (12.4 %) 0.91 (0.79-1.04) 0.15
Efficacy during follow-up (median 25 months)
Cardiovascular death 215 (5.9 %) 229 (6.3 %) 0.94 (0.78 - 1.13) 0.51
Cardiovascular death, cardiogenic shock, Rehosp-MI or new HFa 483 (13.3 %) 521 (14.4 %) 0.92 (0.82-1.05) 0.21
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, definite ST or TVR 615 (17.0 %) 678 (18.7 %) 0.90 (0.81-1.00) 0.058
Safety
Stroke up to 30 days 24 (0.7 %) 27 (0.7 %) 0.89 (0.51-1.54) 0.68
Stroke up to 180 days 42 (1.2 %) 45 (1.2 %) 0.93 (0.61-1.42) 0.75
Stroke until follow up (median 25 months) 89 (2.5 %) 89 (2.5 %) 1.00 (0.75-1.34) 0.99
Net-benefit up to 180 days
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, or strokeb 343 (9.5 %) 371 (10.2 %) 0.92 (079-1.07) 0.27
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, stroke,
definite ST or TVRc
436 (12.0 %) 479 (13.2 %) 0.90 (0.79-1.03) 0.12
Net-benefit during follow-up (median 25 months)
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, or strokeb 545 (15.1 %) 582 (16.1 %) 0.93 (0.83-1.05) 0.24
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, stroke,
definite ST or TVRc
677 (18.7 %) 736 (20.3 %) 0.91 (0.82-1.01) 0.08
aDenotes the primary quadruple composite endpoint within 180 days and also the same quadruple endpoint, during follow up (median 25 months)
bDenotes the net-benefit composite endpoint up to 180 days and during follow-up
cDenotes the extended net-benefit composite endpoint within 180 days and during follow-up
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aspiration in patients undergoing primary PCI for
STEMI to Class III when used routinely and IIb for bail-
out use [17].
Because of the similar findings of the TASTE and
TOTAL trial we now feel confident that with this simple
type of registry based RCT (randomised clinical trial),
the design of TASTE opens up a new venue of performing
randomised clinical trials which can be undertaken at a
fraction of the cost of a classical RCT, and can also be per-
formed exceedingly quickly. Other advantages of basing
Fig. 1 Time to event curves for the primary efficacy quadruple composite endpoint of CV death, cardiogenic shock, new hospitalisation for MI,
and new hospitalisation for HF up to 180 days and to maximal follow up. Illustration of the Kaplan-Meier event curves depicting the cumulative
probability of the composite endpoint of cardiovascular (CV) death, rehospitalisation for new myocardial infarct (MI), cardiogenic shock or new
hospitalisation for heart failure (HF) up to 180 days (Panel a) (Hazard Ratio (HR) 0.93, 95 % CI (0.80-1.09), P = 0.36) or at maximal follow up (mean
25 months) (HR 0.92, 95 % CI (0.82-1.05), P = 0.21) (Panel b) following percutaneous coronary intervention (PCI) with thrombus aspiration (TA) vs.
PCI alone
Olivecrona et al. BMC Cardiovascular Disorders  (2016) 16:62 Page 5 of 10
Fig. 2 (See legend on next page.)
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randomised clinical trials on registries include comparison
to the non-randomised cohort, and continuous follow up
over time.
Thus, published randomised studies and registry
studies as well as meta-analyses of randomised trials
of thrombus aspiration have shown conflicting results
with respect to mortality and other clinical outcomes
[1–4, 14, 18, 19]. All these studies have their limita-
tions, but in the light of the TASTE and TOTAL tri-
als it is now established in our opinion that the
routine use of thrombus aspiration during primary
PCI in STEMI patients conveys no clinical benefit, as
stated in the new guidelines [17].
Why does the current evidence demonstrate a lack of
clinical effect of routine thrombus aspiration in STEMI
patients? This could be explained simply through ineffi-
cient devices or wrong techniques for thrombus aspir-
ation since recent optical coherence tomography (OCT)
findings indicate large amounts of remaining thrombus
following aspiration [20]. There is also the possibility
that microvascular obstruction, which is well correlated
to adverse outcomes, is multifactorial and more dependent
on additional factors such as plaque/debris embolization,
myocardial swelling, spasm or reperfusion injury [21, 22].
Does this mean that no patient should receive thrombus
aspiration? This is currently unknown. Most interven-
tional cardiologists who have aspirated large amounts of
thrombus have difficulty imagining that some of these
procedures were of no benefit to patients. Both the
TASTE trial and TOTAL trial randomised patients to
routine thrombus aspiration. Surprisingly there was no
significant interaction for thrombus score and outcome
of the randomised treatments in either TASTE or
TOTAL, but bailout thrombus aspirations were never-
theless performed in 4.9 % and 7.1 % of patients. Thus,
there may be a small number of patients in which
thrombus aspiration cannot be completely discounted as
beneficial in [23].
Limitations
This is a post hoc retrospective analysis of the prospect-
ive R-RCT TASTE, using non-prespecified endpoints.
As such, the validity of the data is lower than the pro-
spective RCT TOTAL. All clinical events were solely
(See figure on previous page.)
Fig. 2 Time to event curves for the risk of stroke up to 30 and 180 days and to maximal follow up. Kaplan-Meier event curves showing cumulative
probability of the endpoint of stroke up to 30 days (Hazard Ratio (HR) 0.89, 95 % CI (0.51-1.54), P = 0.68) (Panel a), 180 days (HR 0.93, 95 % CI (0.61-1.42),
P = 0.75) (Panel b) and at maximal follow up (mean 25 months) (HR 1.00, 95 % CI (0.75-1.34), P = 0.99) (Panel c) following percutaneous coronary
intervention (PCI) with thrombus aspiration (TA) vs. PCI alone
Fig. 3 Time to event curve for the net-benefit composite endpoint up to 180 days. Kaplan-Meier event curves showing cumulative probability of
the net-benefit outcome up to 180 days of cardiovascular (CV) death, development of cardiogenic shock, rehospitalisation for new myocardial
infarction (MI), new hospitalisation for heart failure (HF) or stroke up to 180 days following percutaneous coronary intervention (PCI) with thrombus
aspiration (TA) vs. PCI alone, Hazard Ratio 0.92, 95 % CI (079-1.07), P = 0.27
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gathered through existing national health registries and
death registries with no adjudication of clinical events.
Because all data were gathered from health and death
registries without monitoring of individual patient files,
we cannot be absolutely certain that there are no miss-
ing data or faulty registrations.
Conclusions
This post hoc analysis of the TASTE study comparing the
quadruple composite endpoint of CV death, rehospitalisa-
tion for new MI, cardiogenic shock and rehospitalisation
for HF up to 180 days between STEMI patients treated
with primary PCI with thrombus aspiration vs. PCI alone
Fig. 4 Time to event curves for the extended net-benefit composite endpoint up to 180 days and to maximal follow up. Illustration of the
Kaplan-Meier event curves depicting the cumulative probability of the composite endpoint of cardiovascular (CV) death, cardiogenic shock,
rehospitalisation for new myocardial infarct (MI), new hospitalisation for heart failure (HF), definite stent thrombosis (ST), target vessel revascularization
(TVR), or stroke up to 180 days (Hazard Ratio (HR) 0.90, 95 % CI (0.79-1.03), P = 0.12) (Panel a) or at maximal follow up (HR 0.91, 95 % CI (0.82-1.01),
P = 0.08) (mean 25 months) (Panel b), following percutaneous coronary intervention (PCI) with thrombus aspiration (TA) vs. PCI alone
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demonstrated no statistical difference in outcome or
difference in stroke rates up to 30 or 180 days.
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